Currently approved prophylactic HPV vaccines

被引：81

作者：

Harper, Diane M. ^{[1
,2
,3
]}

机构：

[1] Univ Missouri, Sch Med, Dept Community & Family Med, Kansas City, MO 64139 USA

[2] Univ Missouri, Sch Med, Dept Obstet & Gynecol, Kansas City, MO 64139 USA

[3] Univ Missouri, Sch Med, Dept Informat & Personalized Med, Kansas City, MO 64139 USA

来源：

EXPERT REVIEW OF VACCINES | 2009年 / 8卷 / 12期

关键词：

cervical cancer; efficacy; HPV; immunogenicity; safety; HUMAN-PAPILLOMAVIRUS HPV; CERVICAL INTRAEPITHELIAL NEOPLASIA; VIRUS-LIKE PARTICLES; COST-EFFECTIVENESS; CONDYLOMATOUS LESIONS; CROSS-PROTECTION; END-POINTS; VACCINATION; CANCER; TYPE-16;

D O I：

10.1586/ERV.09.123

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cervarix (R) and Gardasil (R) are two prophylactic HPV vaccines designed primarily for cervical cancer prevention. Cervarix is effective against HPV-16, -18, -31, -33 and -45, the five most common cancer-causing types, including most causes of adenocarcinoma for which we cannot screen adequately. Gardasil is effective against HPV-16, 18 and 31, three common squamous cell cancer-causing types. In addition, Gardasil is effective against HPV-6 and -11, causes of genital warts and respiratory papillomatosis. The most important determinant of vaccine impact to reduce cervical cancer is its duration of efficacy. To date, Cervarix's efficacy is proven for 6.4 years and Gardasil's for 5 years.

引用

页码：1663 / 1679

页数：17

共 86 条

[1]

[Anonymous], Gardasil

[2]

[Anonymous], 2007, IARC Monographs on the evaluation of carcinogenic risks to humans, V90

[3] Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses [J].

Barnabas, Ruanne V. ;

Laukkanen, Paivi ;

Koskela, Pentti ;

Kontula, Osmo ;

Lehtinen, Matti ;

Garnett, Geoff P. .

PLOS MEDICINE, 2006, 3 (05) :624-632

[4] Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women [J].

Block, Stan L. ;

Nolan, Terry ;

Sattler, Carlos ;

Barr, Eliav ;

Giacoletti, Katherine E. D. ;

Marchant, Colin D. ;

Castellsague, Xavier ;

Rusche, Steven A. ;

Lukac, Suzanne ;

Bryan, Janine T. ;

Cavanaugh, Paul F., Jr. ;

Reisinger, Keith S. .

PEDIATRICS, 2006, 118 (05) :2135-2145

[5] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION [J].

BREITBURD, F ;

KIRNBAUER, R ;

HUBBERT, NL ;

NONNENMACHER, B ;

TRINDINHDESMARQUET, C ;

ORTH, G ;

SCHILLER, JT ;

LOWY, DR .

JOURNAL OF VIROLOGY, 1995, 69 (06) :3959-3963

[6] Anaphylaxis following quadrivalent human papillomavirus vaccination [J].

Brotherton, Julia M. L. ;

Gold, Mike S. ;

Kemp, Andrew S. ;

McIntyre, Peter B. ;

Burgess, Margaret A. ;

Campbell-Lloyd, Sue .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2008, 179 (06) :525-533

[7] The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years [J].

Brown, Darron R. ;

Kjaer, Susanne K. ;

Sigurdsson, Kristjan ;

Iversen, Ole-Erik ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Koutsky, Laura A. ;

Tay, Eng Hseon ;

Garcia, Patricia ;

Ault, Kevin A. ;

Garland, Suzanne M. ;

Leodolter, Sepp ;

Olsson, Sven-Eric ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Paavonen, Jorma ;

Steben, Marc ;

Bosch, F. Xavier ;

Dillner, Joakim ;

Joura, Elmar A. ;

Kurman, Robert J. ;

Majewski, Slawomir ;

Munoz, Nubia ;

Myers, Evan R. ;

Villa, Luisa L. ;

Taddeo, Frank J. ;

Roberts, Christine ;

Tadesse, Amha ;

Bryan, Janine ;

Lupinacci, Lisa C. ;

Giacoletti, Katherine E. D. ;

Sings, Heather L. ;

James, Margaret ;

Hesley, Teresa M. ;

Barra, Eliav .

JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07) :926-935

[8]

Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P997

[9] Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16 [J].

Chen, XJS ;

Garcea, RL ;

Goldberg, I ;

Casini, G ;

Harrison, SC .

MOLECULAR CELL, 2000, 5 (03) :557-567

[10] Cost-effectiveness of human papillomavirus vaccination in the United States [J].

Chesson, Harrell W. ;

Ekwueme, Donatus U. ;

Saraiya, Mona ;

Markowitz, Lauri E. .

EMERGING INFECTIOUS DISEASES, 2008, 14 (02) :244-251

← 1 2 3 4 5 6 7 8 9 →